Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Jianing Wang"'
Autor:
Yajing Wu, Vivek Verma, Carl M. Gay, Yujia Chen, Fei Liang, Qiang Lin, Jianing Wang, Wei Zhang, Zhouguang Hui, Min Zhao, Jun Wang, Joe Y. Chang
Publikováno v:
Cancer.
Autor:
Ke Zhu, Danqian Su, Jianing Wang, Zhouen Cheng, Yiqiao Chin, Luyin Chen, Chingtin Chan, Rongcai Zhang, Tianyu Gao, Xiaosong Ben, Chunxia Jing
Publikováno v:
Frontiers in Oncology. 12
BackgroundImmune checkpoint inhibitors (ICIs) have emerged as a promising treatment option for advanced non-small-cell lung cancer (NSCLC) patients, highlighting the need for biomarkers to identify responders and predict the outcome of ICIs. The purp
Autor:
Yiming Shen, Guowen Zhan, Chongchang Zhou, Hongxia Deng, Yi Shen, Jianing Wang, Jinyun Li, Zhisen Shen
Publikováno v:
Journal of Clinical Laboratory Analysis. 36
Immunotherapy is changing head and neck squamous cell carcinoma (HNSCC) treatment pattern. According to the Chinese Society of Clinical Oncology (CSCO) guidelines, immunotherapy has been deemed as first-line recommendation for recurrent/metastatic HN
Autor:
Linlin Xiao, Yvonne M. Mowery, Brian G. Czito, Yajing Wu, Guangbin Gao, Chang Zhai, Jianing Wang, Jun Wang
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
Autor:
Zhixing Wei, Jianing Wang, Lining Zhang, Xiao Tan, Xiaoyan Wang, Yongyu Shi, Rudi Mao, Ying Xiao, Huaiyu Zhou, Xinyu Wang
Publikováno v:
Cancer Science
Programmed cell death‐ligand 1 (PD‐L1) expressed on cancer cells can cause immune escape of non‐small‐cell lung cancer (NSCLC). Elucidation of the regulatory mechanisms of the PD‐L1 expression is a prerequisite for establishing new tumor im
Autor:
Sishi Peng, Yan Zhao, Y. Yang, Jianjun Zou, Xiuting Liu, Yubing Zhu, Zhaoying Yao, Xinliang Qu, Qiongyu Mi, Shuli Zhao, Xu Zhang, Chao Liu, Qianming Du, Jianing Wang, Yan Zhang, Bangshun He
Publikováno v:
Cancer Letters. 470:29-42
5-fluorouracil (5-FU) is widely used in chemotherapy for colorectal cancer (CRC), but a high rate of chemoresistance reduces its effectiveness in clinical treatment. We found remarkably decreased expression of forkhead box 3 (FoxO3) protein, a tumor
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
BackgroundConcurrent chemoradiotherapy (CCRT) has become the standard of care in esophageal carcinoma patients who are not surgical candidates. The efficacy of induction chemotherapy (IC) or consolidation chemotherapy (CCT) for unresectable esophagea
Autor:
Na Li, Yongyu Shi, Jianing Wang, Jiahuan Zou, Zhida Wang, Xiaopeng Yu, Lining Zhang, Huaiyu Zhou, Xiaoyan Wang, Rudi Mao, Mengwei Zhuang
Publikováno v:
Molecular Immunology. 101:203-209
The effectiveness of immunotherapy targeting the immune checkpoint PD-L1/PD-1 pathway highlights importance of elucidating the regulatory mechanisms of PD-L1 expression in cancer cells. Previous studies demonstrate that oncogene MYC up-regulates PD-L
Autor:
Linlin Xiao, Jianing Wang, Jun Wang, Yajing Wu, Brian G. Czito, Chang Zhai, Yvonne M. Mowery, Guangbin Gao
Publikováno v:
Frontiers in Oncology
Frontiers in Oncology, Vol 11 (2021)
Frontiers in Oncology, Vol 11 (2021)
PurposeDue to the low incidence of intracranial disease among patients with esophageal cancer (EC), optimal management for these patients has not been established. The aim of this real-world study is to describe the clinical characteristics, treatmen
Publikováno v:
Cancer letters. 511
A20 is a prototypical anti-inflammatory molecule that is linked to multiple human diseases, including cancers. The role of A20 as a tumor suppressor was first discovered in B cell lymphomas. Subsequent studies revealed the dual roles of A20 in solid